RAD BioMed

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.

CVAid Medical focuses on developing an artificial intelligence-based platform aimed at enhancing stroke detection and triage. This technological solution is designed to improve the diagnosis of strokes, ultimately saving lives by facilitating early intervention. The company's approach encompasses the entire process, starting from pre-hospital early diagnosis, through in-hospital management, and extending to follow-up care after discharge. By providing tools that assist both physicians and patients, CVAid Medical aims to improve treatment outcomes through timely and effective stroke management.

BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, established in 2011. The company specializes in developing and manufacturing advanced cardiac monitoring systems for patients with congestive heart failure. Its flagship product, the V-LAP, is the world's first in-heart microcomputer that provides daily, push-button readings of left atrial pressure (LAP), the earliest and most reliable indicator of heart failure deterioration. This innovative device is miniature, wireless, and battery-less, allowing it to communicate effectively from within the body. Vectorious is currently conducting clinical trials in several European countries, including Italy, Germany, and the UK, aiming to obtain a CE mark for its product. Additionally, plans for a clinical study in the United States were anticipated to commence in 2020. Through its technology, Vectorious aims to enhance the quality of life and life expectancy for individuals suffering from heart failure.

SoftWheel LTD. is a technology company based in Tel Aviv, Israel, specializing in the development of advanced in-wheel suspension technology for the wheelchair, bicycle, and automotive sectors. Founded in 2011, the company designs innovative suspension systems that absorb shocks and vibrations, enhancing comfort and performance for users, particularly in wheelchairs. SoftWheel's products also contribute to improvements in energy efficiency and overall mobility. The company markets its suspension arms and wheel rims through a network of resellers both in Israel and internationally. To strengthen its position in the market, SoftWheel has established strategic partnerships with notable global firms, including NSK and Linamar.

Advanced Ophthalmic Pharma Ltd., a biomedical company, develops technologies in ophthalmology. It offers Eye AdMister, a drug delivery device, enables the mist application of preservative-free ophthalmic drug formulations for eye care. The company was founded in 2007 and is based in Tel Aviv, Israel.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.